Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease.

Jadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, Luongo TS, Ludtmann MH, Praticò D, Elrod JW. · 2019

Read Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. by Jadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, Luongo TS, Ludtmann MH, Praticò D, Elrod JW. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6715724.txt.

Introduction

Jadiya and co-authors studied how faulty calcium handling in mitochondria may drive Alzheimer's disease. Mitochondria are the cell's power units, and calcium signals help run them. In brain tissue from people with Alzheimer's, the team found the calcium exit machinery remodeled. A mouse model of the disease showed the same flaw early.

The exit route is a protein called NCLX. Deleting it in mouse neurons sped memory loss and raised amyloid and tau damage. Restoring it did the reverse, protecting memory and cutting pathology. Calcium overload, they show, fuels harmful oxygen byproducts and cell death. The exit protein is put forward as a drug target.

Catalog record

CREATORJadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, Luongo TS, Ludtmann MH, Praticò D, Elrod JW.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE81 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6715724

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer’s disease By Pooja Jadiya, Devin W Kolmetzky, Dhanendra Tomar, Antonio Di Meco, Alyssa A Lombardi, Jonathan P Lambert, Timothy S Luongo, Marthe H Ludtmann, Domenico Praticò, John W Elrod Published in: Nature Communications DOI: 10.1038/s41467-019-11813-6 ABSTRACT Abstract Impairments in neuronal intracellular calcium (iCa2+) handling may contribute to Alzheimer’s disease (AD) development. Metabolic dysfunction and progressive neuronal loss are associated with AD progression, and mitochondrial calcium (mCa2+) signaling is a key regulator of both of these processes. Here, we report remodeling of the mCa2+ exchange machinery in the prefrontal cortex of individuals with AD. In the 3xTg-AD mouse model impaired mCa2+ efflux capacity precedes neuropathology. Neuronal deletion of the mitochondrial Na+/Ca2+ exchanger (NCLX, Slc8b1 gene) accelerated memory decline and increased amyloidosis and tau pathology. Further, genetic rescue of neuronal NCLX in 3xTg-AD mice is sufficient to impede AD-associated pathology and memory loss. We show that mCa2+ overload contributes to AD progression by promoting superoxide generation, metabolic dysfunction and neuronal cell death. These results provide a link between the calcium dysregulation and metabolic dysfunction hypotheses of AD and suggest mCa2+ exchange as potential therapeutic target in AD. Subject terms: Calcium signalling, Energy metabolism, Alzheimer's disease INTRODUCTION Alzheimer’s disease (AD) is an age-associated multifactorial disease characterized by two major pathological hallmarks, senile plaques composed of extracellular β-amyloid (Aβ) and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. These protein aggregates are thought to trigger neurodegeneration, resulting in loss of memory and cognitive skills in both sporadic and familial forms of AD1. Over the past two decades, there has been progress in identifying various cellular mechanisms contributing to AD pathogenesis, but at present the underlying cause is unknown and thus far therapeutic strategies targeting Aβ and tau pathways have failed2,3. It is widely accepted that intracellular calcium (iCa2+) signaling has an essential role in synaptic transmission and neuronal intra- and paracellular communication. The majority of neuronal ATP is consumed to modulate ion flux at the plasma membrane and ER to control iCa2+ levels4. Given the essential nature of Ca2+ regulation to cellular homeostasis, it is not surprising that alterations in Ca2+ handling have been reported to be a central feature of neurodegeneration and age-related diseases5. Numerous reports of Ca2+ dysregulation coalesced into the formation of the “calcium hypothesis of aging and AD”6,7. The calcium hypothesis theorizes that alterations in Ca2+ handling, leading to elevations in iCa2+, are a central mechanism linking amyloid metabolism to neuronal cell death and cognitive decline. Indeed, numerous molecular mechanisms have been shown to contribute to amyloid-mediated impairments in Ca2+ regulation at multiple cellular levels including: altered SERCA activity, increased ryanodine receptor leak8, and increased inositol 1,4,5-trisphosphate receptor activity at the ER9, the dysregulation of voltage-operated channels such as calcium homeostasis modulator 110, altered receptor-dependent Ca2+ signaling (nicotinic acetylcholine receptors, N-methyl-d-aspartate receptors7 and amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors11 and the dysregulation of store-operated calcium entry at the plasma membrane12. Inversely, there is growing evidence that Ca2+ dysregulation is upstream in the disease process and perhaps precede amyloidogenic disease. This has prompted some investigators to propose that impairments in Ca2+ regulation may actually drive AD development13,14. Regardless, there is clear evidence of Ca2+ dysregulation with numerous studies suggesting neurons are subjected to elevated iCa2+ levels in AD. This increase in iCa2+ coupled with alterations in ER/mitochondria tethering,15,16 is theorized to cause mitochondrial calcium (mCa2+) overload, which is linked to: excessive reactive oxygen species (ROS) generation, metabolic derangement, and mitochondrial dysfunction, all prominent features of AD pathogenesis. In addition, it is widely recognized that mCa2+ can directly influence cell death signaling by activating the mitochondrial permeability transition pore and Ca2+ dependent proteases (calpains), and indirectly through its effects on superoxide generation and ATP availability17–20. Although several studies have proposed that mitochondrial dysfunction is a primary trigger for AD development17,21 to date no causal studies have directly implicated alterations in mCa2+ exchange with AD or examined the direct contribution of mCa2+ signaling with disease progression. The mitochondrial Na+/Ca2+ exchanger (NCLX) is the primary mechanism for mCa2+ efflux in excitable cells22,23, and thereby is an excellent target to modulate mCa2+ load in neurons. Here, we provide evidence that mCa2+ efflux is impaired in an age-dependent fashion in multiple experimental models of AD and that NCLX expression is lost in the frontal cortex of non-familial/sporadic AD patients. Our data suggest that the dysregulation of mitochondrial calcium efflux precedes neuropathology and memory decline in AD. We propose that these results provide a missing link between the “calcium dysregulation” and “mitochondrial dysfunction” hypotheses and advocate targeting mitochondrial calcium exchange as a powerful therapeutic to inhibit or reverse AD progression. RESULTS Loss of NCLX expression correlates with AD progression Frontal cortex samples were collected postmortem from non-familial, sporadic AD patients, and age-matched controls with no history of dementia and probed for alterations in the expression of mitochondrial calcium handling genes. Interestingly, we observed a substantial reduction in the expression of NCLX, the primary mediator of mCa2+ efflux in excitable cells (Fig. 1a). In addition, we observed a reduction in the mitochondrial calcium uniporter channel (mtCU)-associated proteins: MICU1 and MCUB. The voltage-dependent anion channel (VDAC) and Complex V-Sα (CV-Sα) served as mitochondrial loading controls. Next, we examined mCa2+ transporter expression in a well characterized, robust murine model of AD to determine whether these alterations preceeded or coincided with neurohistopathology and behavior deficits. We acquired mutant mice harboring three gene mutations associated with familial AD (3xTg-AD): Presenilin 1 (Psen1, M146V homozygous knock-in), amyloid beta precursor protein (APPswe, KM670/671NL transgene) and microtubule associated protein tau (MAPT, P301L transgene). These mice develop age-progressive pathology similar to that observed in AD patients including: impaired synaptic transmission, Aβ deposition, plaque/tangle histopathology, and learning/memory deficits beginning ~6 months of age24. mRNA and protein were isolated from brain tissue derived from the frontal cortex and hippocampus of 2, 4, 8, and 12-month-old 3xTg-AD mutant mice and outbred age-matched, non-transgenic controls. 3xTg-AD mice displayed an age-dependent reduction in NCLX expression with a significant decrease noted as early as 4 months and near complete loss of mRNA and protein by 12 months of age (Fig. 1b, c; Supplementary Fig. 1A–D). Importantly, we found no significant alteration in the expression of any transporters associated with mCa2+ exchange in samples isolated from the brains of 2-month-old 3xTg-AD mice, an age prior to any detectable neuropathology or memory deficits25 (Fig. 1b; Supplementary Fig. 1a, e). These results suggest the changes in gene expression are age-dependent and not merely the result of developmental expression changes associated with this mutant model. The loss of the key mCa2+ efflux mediator, NCLX, and decrease in the expression of negative regulators of the mtCU, MICU1 (gatekeeper of mtCU to limit uptake at low iCa2+ and augmenter of uptake at high iCa2+ levels26–29) and MCUB30, is likely to promote increased [mCa2+] levels; especially in the high iCa2+ environment that is reported to occur in neurons during AD progression6. These alterations are in stark contrast to the compensatory alterations we have previously reported in cardiac biopsies isolated from failing hearts at the time of transplant22, and suggest that in AD, changes in the expression profile of mCa2+ transporters may contribute to matrix Ca2+ overload and disease development. [Figure: NCLX

Read the complete text